<DOC>
	<DOCNO>NCT00093704</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes necessary growth . The Epstein Barr virus cause cancer lymphoproliferative disorder . Ganciclovir antiviral drug act Epstein Barr virus . Giving ganciclovir together bortezomib may kill Epstein Barr virus-infected cancer cell . PURPOSE : This clinical trial study well give bortezomib together ganciclovir work treat patient relapsed refractory Epstein Barr virus-positive lymphoma .</brief_summary>
	<brief_title>Bortezomib Ganciclovir Treating Patients With Relapsed Refractory Epstein Barr Virus-Positive Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Maximum Tolerated Dose ( MTD ) bortezomib patient relapse refractory Epstein Barr virus-positive lymphoma . Secondary - Assess antitumor effect regimen patient . OUTLINE : This pilot , open-label , dose-escalation study bortezomib . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 11 . Patients also receive ganciclovir IV twice daily day 1-14 . Treatment repeat every 21 day maximum 3 course . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 3-9 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Histologically confirm Epstein Barr viruspositive lymphoma , include follow subtypes : Posttransplantation lymphoma Burkitt 's lymphoma Hodgkin 's lymphoma T/NKcell lymphoma Unresponsive , relapse , least 1 prior chemotherapy regimen Bidimensionally measurable disease CT scan At least 1 lesion ≥ 1.5 cm great diameter Age 18 ECOG 02 OR Karnofsky 50100 % Life expectancy More 3 month Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 ( growth factor support within past 4 week ) Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 50,000/mm^3 ( platelet transfusion within past 4 week ) Hepatic Bilirubin ≤ 2.0 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( 5 time ULN patient liver involvement ) No active hepatitis B C Renal Creatinine clearance ≥ 60 mL/min Sodium &gt; 130 mmol/L Negative pregnancy test Fertile patient must use effective contraception HIV negative At least 4 week since prior immunotherapy At least 4 week since prior chemotherapy At least 4 week since prior radiotherapy More 4 week since prior major surgery unless fully recover Recovered prior therapy At least 4 week since prior investigational agent primary secondary CNS lymphoma HIVrelated lymphoma know brain metastasis myocardial infarction within past 6 month acute ischemia new conduction system abnormalities electrocardiogram symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia hospitalize pregnant nursing uncontrolled illness ongoing active systemic infection psychiatric illness social situation would preclude study compliance history allergic reaction attributable compound similar chemical biological composition study drug sensitivity boron , mannitol , bortezomib , ganciclovir concurrent corticosteroid ( ≥ 10 mg prednisone equivalent ) concurrent radiotherapy concurrent anticancer therapy concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
</DOC>